Myopia, or nearsightedness, is a condition in which close objects appear clear while distant ones look blurry. It typically develops during childhood and may progress rapidly, leading to high myopia — which may increase the risk of serious eye complications later in life.¹ Early intervention is therefore critical in helping manage this progression.²

Introducing Essilor^® Stellest^® Lenses

The Essilor Stellest lens is the first and only FDA market authorized spectacle lens to slow the progression of nearsightedness in children.*

How Essilor Stellest Lenses Work

Essilor Stellest lenses don’t just correct vision—they help slow myopia progression in children*, thanks to Highly Aspherical Lenslet Target (H.A.L.T.) technology.^† This advanced optical design features:

• A single vision zone to correct myopia and provide clear, sharp vision.
• A constellation of 1,021 highly aspherical lenslets, spread across 11 rings, covering 40% of the lens surface.

Light passing through these lenslets creates a volume of myopic defocus that follows the shape of a child’s theoretical myopic retina.⁵ This optical signal helps slow the elongation of the eye — the primary factor driving myopia progression.

Clinically Proven Results

Essilor Stellest lenses are supported by a prospective, randomized, double-masked, multicenter U.S. clinical trial involving children aged 6–12 years at the start of treatment.

Over a two-year period, results demonstrated:

• Slowed myopia progression by 71% on average compared to single vision lenses (p < 0.0001).*
• Slowed axial elongation by 53% with an average reduction of 0.24 mm (p < 0.0001).*

These results confirm that Essilor Stellest lenses are clinically proven to slow myopia progression in children while providing visual acuity and comfort.*

Recommended Use

For optimal benefit, children are recommended to wear their Essilor Stellest spectacle lenses for at least 10 hours per day, six days per week, and maintain regular eye examinations.⁴
Outdoor time — at least 2 hours per day — is also encouraged to support healthy visual development.⁴

Why Choose Essilor Stellest Lenses

• Clinically proven to slow myopia progression in children*
• First and only FDA market authorized spectacle lens for this purpose*
• Non-invasive, everyday solution to slow myopia progression*
• Developed by Essilor, a global leader in optical innovation
• Seamless to prescribe, simple to dispense, proven to perform*

Essilor Stellest lenses represent the breakthrough^‡ in children’s eye care that parents have been waiting for.

The Takeaway

As childhood myopia rates continue to rise, proactive management has never been more important. With Essilor Stellest lenses, parents and eye care professionals have access to a trusted, science-backed solution that offers both correction and long-term protection for children’s vision.

If your child has been diagnosed with myopia, speak with your eye care professional to see if Essilor Stellest lenses are right for them.

The Stellest is available now and can be ordered here at IcareLabs.

*Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6-12 years at initiation of treatment.

†H.A.L.T. is an acronym for Highly Aspherical Lenslet Target and does not imply a “halt” or “stop” of myopia progression.

‡The U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the Essilor^® Stellest^® spectacle lens in April 2021.

References

1. Gifford KL et al. IMI–Clinical management guidelines report. Invest Ophthalmol Vis Sci. 2019;60(3):M184–203.
2. Sankaridurg P. A less myopic future: what are the prospects? Clin Exp Optom. 2015;98(6):494–6.
3. Essilor International, data on file (2025).
4. Essilor International. Essilor^® Stellest^® spectacle lenses: Professional fitting and information guide. Instructions for Use. Sept 2025.
5. Atchison DA. Optical models for human myopic eyes. Vision Res. 2006;46:2236–50.

Essilor^® and Stellest^® are trademarks of Essilor International.
© Essilor International – October 2025.